Axtria Blogs

Blogs By Natasha Kulkarni

Blog thumbnail

Quantifying the Impact of Delaying Treatment

When new drugs enter the market, there are often delays before patients have access to the medication. These delays are partly due to patients and physicians being required to complete several steps before a prescription is approved for reimbursement. Alirocumab, a PCSK9 inhibitor which reduces low-density lipoprotein cholesterol (LDL-C)1, has up to a 75% rejection rate by payers2. The natural question that follows is what impact this delay may have on a patient’s health.

Read More

Let Us Show You What Axtria’s 

Solutions Can Do For You